<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191228045924N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-10</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of repairing gel and platelet-fibrin glue in the healing of wounds</public_title>
      <acronym></acronym>
      <scientific_title>Increasing the effectiveness of platelet-fibrin glue in the healing of recalcitrant wounds by adding the repairing gel which has the approved components in wound healing</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70780</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: The blocked method is used to avoid significant imbalances in the number of participants assigned to each group. Block randomization ensures that there is no significant imbalance between groups at any time during randomization, and at certain points the number of participants in each group is equal.
Random number table using www.randomization.com
In the random block method, 10 blocks of four of different permutations of letters ABCD are considered, and patients are divided into four groups accordingly.
Randomization Type: Blocked
Allocation Concealment method
The sealed envelope is used as a means of randomization and concealment. The method of sealed envelopes is that the envelopes will be prepared and printed by a member of the research team and random numbers with the help of Randomaize.com and placed inside the envelope. The lid of the envelopes will be closed and its contents will not be visible from the outside. First, the purpose of the study is explained to the person who meets the stated conditions, and if the person wishes, he signs the informed consent form and takes an envelope, and then opens it based on the contents of the envelope, the person is in group 1 or 2 or 3 or 4 is entered, Blinding description: First, this study is explained to the participants it is a three-blind study and includes three intervention groups and one control group.
40 patients with chronic wounds, who did not respond to classical treatment after 3 months and the damage is still not healed, are included in the study. 10 patients in each group: Group 1 (fibrin glue) - Group 2 (repairing gel) - Group 3: (platelets-fibrin glue and repairing gel) - Group 4: (classic wound irrigation treatment). 
The participants will not know which group they belong to. The statistical analyzer and evaluator are not also informed about the groups.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Chronic Wound.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: 10 patients with chronic wounds, the classical treatment will be performed, and then platelet-fibrin glue in the form of gel will be placed on the patient's wound. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound. Fibrin glue is prepared in the clean room of skin bank of Imam Reza Hospital. Intervention 2: Second intervention group: 10 patients with chronic wounds, the classical treatment for the wound will be performed, and the repairing gel with approved wound healing components in the form of gel will be used. The repairing gel will be manufactured by Omid Rajabi Pharmaceutical Factory, and the dosage of the components used is FDA-approved. The components are vitamin A (0.2 percent) - vitamin C (2 percent) - vitamin B3 (0.5 percent) - glycine amino acid. (0.5 percent) - ethanol (2 percent) - collagen (1 percent) - citric acid (2 percent) - glycerin (0.5 percent) - malic acid (1 percent) - urea (35 percent) - carboxymethyl cellulose (2 percent) - Sodium alginate (1 percent) - Benzoic acid (0.002 percent) - Propylene glycol (0.5 percent) -  Methylene blue (0.1 percent) - Violet Dujancin (0.1%) - dimethyl sulfoxide (0.1%), which is prepared as a gel. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound. Intervention 3: Third intervention group:10 patients with chronic wounds, in addition to the classical treatment, the repairing gel with approved wound healing components and platelet-fibrin glue will be placed on the wound. The repairing gel will be manufactured by Omid Rajabi Pharmaceutical Factory, and the dosage of the components used is FDA-approved. The components are vitamin A (0.2 percent) - vitamin C (2 percent) - vitamin B3 (0.5 percent) - glycine amino acid. (0.5 percent) - ethanol (2 percent) - collagen (1 percent) - citric acid (2 percent) - glycerin (0.5 percent) - malic acid (1 percent) - urea (35 percent) - carboxymethyl cellulose (2 percent) - Sodium alginate (1 percent) - Benzoic acid (0.002 percent) - Propylene glycol (0.5 percent) - Methylene blue (0.1 percent) - Violet Dujancin (0.1%) - dimethyl sulfoxide (0.1%), which is prepared as a gel. Fibrin glue is prepared in the clean room of skin bank of Imam Reza Hospital. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound. Intervention 4: Control group:  10 patients with chronic wounds, only the classical wound irrigation will be continued.   The number of times of use: Every 48 hours for 8 weeks, the dressing is changed on the wound.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Daryoush Hamidi Alamdari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshgah Street, Surgical Oncology Research Center, Mashhad University of Medical Sciences, General Surgery Department, Building No. 2, Imam Reza hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9133913716</zip>
        <telephone>+98 915 101 7650</telephone>
        <email>hamidiad@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Daryoush Hamidi Alamdari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Iman Reza Hospital, Daneshgah Ave</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>+98 51 3882 8574</telephone>
        <email>hamidiad@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having a single wound on the body that has been at least 3 months old and has not been repaired by wound irrigation with normal saline and changing the dressing
Having a body mass index of 18-35
Sign the informed consent by patient</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having concurrent diseases that may cause problems in wound healing, such as cancers, vasculitis, kidney and liver failure, and heart failure
Taking certain drugs that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T01.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple open wounds, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: 10 patients with chronic wounds, the classical treatment will be performed, and then platelet-fibrin glue in the form of gel will be placed on the patient's wound. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound. Fibrin glue is prepared in the clean room of skin bank of Imam Reza Hospital.</i_keyword>
      <i_keyword>Second intervention group: 10 patients with chronic wounds, the classical treatment for the wound will be performed, and the repairing gel with approved wound healing components in the form of gel will be used. The repairing gel will be manufactured by Omid Rajabi Pharmaceutical Factory, and the dosage of the components used is FDA-approved. The components are vitamin A (0.2 percent) - vitamin C (2 percent) - vitamin B3 (0.5 percent) - glycine amino acid. (0.5 percent) - ethanol (2 percent) - collagen (1 percent) - citric acid (2 percent) - glycerin (0.5 percent) - malic acid (1 percent) - urea (35 percent) - carboxymethyl cellulose (2 percent) - Sodium alginate (1 percent) - Benzoic acid (0.002 percent) - Propylene glycol (0.5 percent) -  Methylene blue (0.1 percent) - Violet Dujancin (0.1%) - dimethyl sulfoxide (0.1%), which is prepared as a gel. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound.</i_keyword>
      <i_keyword>Third intervention group:10 patients with chronic wounds, in addition to the classical treatment, the repairing gel with approved wound healing components and platelet-fibrin glue will be placed on the wound. The repairing gel will be manufactured by Omid Rajabi Pharmaceutical Factory, and the dosage of the components used is FDA-approved. The components are vitamin A (0.2 percent) - vitamin C (2 percent) - vitamin B3 (0.5 percent) - glycine amino acid. (0.5 percent) - ethanol (2 percent) - collagen (1 percent) - citric acid (2 percent) - glycerin (0.5 percent) - malic acid (1 percent) - urea (35 percent) - carboxymethyl cellulose (2 percent) - Sodium alginate (1 percent) - Benzoic acid (0.002 percent) - Propylene glycol (0.5 percent) - Methylene blue (0.1 percent) - Violet Dujancin (0.1%) - dimethyl sulfoxide (0.1%), which is prepared as a gel. Fibrin glue is prepared in the clean room of skin bank of Imam Reza Hospital. The number of times of use: use of repairing gel and fibrin gel is every 48 hours for 8 weeks, and these gels are used on the wound at the time of changing the dressing after irrigation of the wound.</i_keyword>
      <i_keyword>Control group:  10 patients with chronic wounds, only the classical wound irrigation will be continued.   The number of times of use: Every 48 hours for 8 weeks, the dressing is changed on the wound.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of pain. Timepoint: It is measured after two days of changing the dressing. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>The duration of recovery, which is the number of days it takes for the wound to heal. Timepoint: Every 24 hours (every day). Method of measurement: By visual observation.</prim_outcome>
      <prim_outcome>Presence of inflammation and infection. Timepoint: Before the intervention and after the intervention every week for two month. Method of measurement: Clinical examination.</prim_outcome>
      <prim_outcome>Quality of Life. Timepoint: Before the intervention and after the intervention. Method of measurement: Completing the SF36 questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Reepithelialisation and wound closure. Timepoint: Every week for two month after dressing. Method of measurement: Clinical observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-17</approval_date>
        <contact_name>Research Ethics committees of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Daneshgah street, the central organization of University, Quraishi Building Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
